Purpose Due to diagnosis at advanced stages, comorbidities, and the impact of treatment, patients with hepatocellular carcinoma (HCC) may experience pain. The purpose of this study was to evaluate the psychometric properties of a brief, clinically relevant measure of pain in HCC.
Introduction
Hepatocellular carcinoma (HCC) is a primary hepatic malignancy that often arises as a result of liver cirrhosis. The incidence of HCC has been increasing in recent years, and it is currently the second leading cause of cancer death worldwide and results in a significant number of cancer deaths in the USA [1] . Choice of treatment for HCC depends largely on stage of disease, patient comorbidities, and center-specific expertise.
While mortality and medical morbidity should be central components of treatment decision-making, incorporating patient-reported outcomes (PROs) would add relevant depth to treatment decisions. Indeed, PROs assessing patient symptoms and other aspects of health-related quality of life (HRQOL) hold promise for increasing our understanding of the most important symptoms and concerns for patients with HCC, as well as the impact of therapy on HCC symptoms and HRQOL [1] . In turn, this information can contribute to evaluations of the comparative effectiveness of HCC therapies.
Health-related quality of life refers to the subjective experience and well-being of a patient as affected by a medical condition or its treatment [2] . HRQOL for HCC has been examined in the literature [1, [3] [4] [5] ; however, there remain a number of open questions regarding the impact of therapeutic intervention on patient HRQOL over time, especially with respect to pain, which some patients experience due to advanced disease at diagnosis, comorbid diseases, and the impact of therapy [1, 3] .
The Functional Assessment of Cancer Therapy-Hepatobiliary is a 45-item questionnaire that includes the 27-item FACT-General (FACT-G) and an 18 item hepatobiliary-specific subscale [6, 7] . The items on the FACTHep were developed on the basis of expert clinician and patient input, ensuring its content validity and clinical relevance for hepatobiliary cancers, like HCC. In its original form, the scale has specifically been used to assess the QOL impact of HCC treatment [8] , but briefer versions of the scale have been developed for patients with advanced stages of the disease [9] .
To our knowledge, there exists no pain scale-specific for patients with HCC or derived from input from patients with HCC. Based on our group's recent qualitative analysis [10] , we believe three items from the FACT-Hep hold promise to measure clinically significant pain symptoms for patients with HCC. In addition, several investigators select the FACT-Hep as their multidimensional health-related quality of life measure of choice and would benefit from an embedded, relevant, and responsive pain scale. This would spare patients on those trials the burden of unnecessary added assessment created by adding a pain measure.
The goal of the present study was to test a clinically relevant pain assessment for people with HCC, derived from items from the FACT-Hep. Such a measure would improve meaningful integration of pain assessment in clinical research on and care of patients with HCC.
Methods

Participants: secondary data
We conducted quantitative analysis of existing data from four studies to support the development of a brief pain scale for patients with HCC. Specifically, we analyzed deidentified patient-reported outcome and clinical data previously collected at the University of Pittsburgh Medical Center (UPMC). The original purpose for measuring PROs for the UPMC studies was to characterize the longitudinal changes in health-related quality of life among patients with HCC. A summary of findings from the original research can be found in several published manuscripts [5, [11] [12] [13] [14] . Table 1 summarizes the source of the unique patients. All participants with available data were included in our analysis. The studies did have different follow-up periods, but at a minimum were followed for a year. The average survival for the patients in the included studies was 11 months. Our focus for the current manuscript was measurement of pain, which was not described in detail in the original manuscripts.
Measures
Functional assessment of cancer therapy-hepatobiliary (FACT-Hep)
The FACT-Hepatobiliary (FACT-Hep) is a 45-item questionnaire that includes the 27-item FACT-G and an 18 item hepatobiliary-specific subscale. The FACT-G is a general cancer health-related quality of life questionnaire that assesses physical well-being (PWB; seven items), social/ family well-being (SWB; seven items), emotional wellbeing (EWB; six items), and functional well-being (FWB; seven items). Scores were calculated according to developers' instructions. Specifically, negatively worded items were first reverse scored such that a high score corresponds to better quality of life for all items and subscale scores. If more than 50 % of the items in a subscale were completed, missing item responses were imputed using the mean of completed items [6, 7] . Item scores were then summed to create subscale scores.
Three items on the FACT-Hep assess pain: GP4 (I have pain), CNS7 (I have pain in my back), and Hep8 (I have discomfort or pain in my stomach area). A three-item pain subscale score was calculated according to the same scoring guidelines and had a possible score range of 0-12 (with lower scores indicating more pain). Our focus in the present manuscript is to report on the relevance and validity of this particular subset of existing questions.
Brief Pain Inventory
The Brief Pain Inventory (BPI) is a self-report instrument that assesses the severity of pain and its impact on daily functions. It has been validated in patients with cancer and other chronic illnesses [15] . Pain severity can be measured by the ''worst pain'' item for the mean of the four severity items; scores of 5-6 indicate moderate pain, and scores of 7-10 indicate severe pain. Pain interference can be summarized by the mean of the seven interference items. A total of 53 patients had some available BPI data, with 49 having complete data to derive BPI interference scale scores.
Statistical analysis
Descriptive statistics
Available sociodemographic and clinical characteristics of the sample were summarized. Descriptive statistics (mean, standard deviation, median, minimum, and maximum) were calculated for all subscale scores.
Internal consistency reliability
Cronbach's coefficient alpha was calculated to evaluate the internal consistency reliability of the pain items. Cronbach's coefficient alpha is a measure of how closely correlated a set of items are with each other. A Cronbach's coefficient alpha of 0.70 or greater is generally considered acceptable [16] . We examined item-total correlations to identify items poorly correlated with the total score.
Dimensionality and model fit
We first evaluated the unidimensionality of the three pain items using confirmatory factor analysis (CFA) as implemented in MPlus. The criteria that were used in this analysis are as follows: comparative fit index (CFI) [0.9; root mean square error of approximation (RMSEAs) \0.08; R 2 [ 0.3 and modification indices (MI) \10 [17] [18] [19] [20] . Once the unidimensionality was confirmed, Rasch analysis [21] , in particular Andrich's partial credit model [22] as implemented in the WINSTEPS computer program, was used to evaluate the characteristics of the FACT-Hep pain items. Fit statistics for each item, reported as MnSq (criterion between 0.6 and 1.4), were used to evaluate whether the items fit the Rasch model.
Item and scale information
Item information curves (IICs) were generated for each of the three items to characterize the magnitude of information and precision in distinguishing respondents on that item, along the pain measurement continuum. Further, the item information function of each item was aggregated to generate the pain subscale information function curve. The subscale information function curve characterizes the range of the pain domain over which responses to the pain items are best able to distinguish. The scale information function is influenced by the number of items included in the scale. Given that the current pain scale only consists of three items, we report scale information functions for informational purposes only.
Convergent validity
We hypothesized that the pain scores would be associated with general health-related quality of life, as measured by the FACT-G. The association between the pain scores and the FACT-G was evaluated using Pearson's correlations. Moderate correlations in the range of 0.3-0.7 were expected.
Results
Descriptive statistics
The sociodemographic and clinical characteristics of the 304 patients included in the sample are summarized in Table 1 . Descriptive statistics were calculated for all subscale scores and summarized in Table 2 . As shown in Fig. 1 , the majority of patients reported having ''none'' or ''a little bit'' of pain on the three-item pain scale derived from the FACT-Hep. Among these 304 patients, 76 showed extreme scores (74 with no pain, 2 with maximum pain, as assessed by these items).
Internal consistency reliability
Cronbach's coefficient alpha for the three pain items was 0.69 at time 1 (n = 295), 0.84 at time 2 (n = 125), 0.81 at time 3 (n = 75), and 0.81 at time 4 (n = 59). Item-total correlations at each time did not indicate any poorly performing items. Pearson's correlation coefficients across the Results of one-factor CFA supported the unidimensionality of these three pain items are as follows: CFI = 1 (criterion [0.90), RMSEA = 0.00 (criterion \0.08), R 2 [ 0.3 (range 0.341-0.832). With residual correlations from the CFA \ 0.01 and MI all \10, local independence among these three items was also supported.
In Rasch analysis, at the item level, all items had acceptable fit with MnSq ranging from 0.84 to 1.18 (criterion \1.4). The mean person measure was 1.23 logit (SD = 1.57) when all respondents were included. When extreme scores were removed (n = 74 extreme high scores and n = 2 extreme low scores), the mean person measure was 0.55 logit (SD = 1.02). Table 3 shows the item locations and threshold locations for the three items. Figures 2,  3 and 4 depict category characteristic curves of the rating scale for each item. Each curve represents a response category. Since a 5-point rating scale was used, each figure consisted of five curves showing the probability of patients that endorsed each rating at a given latent trait (pain) level (i.e., X-axis) with higher levels showing lower pain. As shown in Figs. 2 and 4 , each curve was distinguished from each other with ranking of responses in the correct order, satisfying monotonicity. In Fig. 3 , the curve representing the response category 2 did not have significant peak compared the rest of other four categories. The measures of intersection between two adjacent categories were -0.69 (categories 0 and 1; SE = 0.28), -0.81 (categories 1 and 2; SE = 0.21), 0.19 (categories 2 and 3; SE = 0.17), and 0.76 (categories 3 and 4; SE = 0.17). Taking into account the SEs, we concluded this rating scale was valid for measuring this item. Figure 5 is an ''item-person map'' that compares whether pain experienced by participants (farthest left column) were fully captured by the pain measurement continuum, as defined by these items. Locations of items on the pain continuum are displayed based on the 50 % of probability that patients endorsed the highest (''TOP P = 50 %''), average of all five (''MEASURE''), and lowest (''BOT-TOM P = 50 %'') response category. Specifically, a patient with a measure of 0.5 logit will have \50 % of chance to endorse the highest category while on the other hand, [50 % to endorse the rest of response categories. As Table 3 Item locations, fit statistics, and step intercepts
Item
Item location MNSQ Step 1
Step 2
Step 3
Step 4 
Step'' represents the intercept between two adjunct response categories. Specifically, ''step 1'' is the intercept between response ''0'' and ''1''; ''step 2'' is for response ''1'' and ''2''; ''step 3'' is for response ''2'' and ''3''; and ''step 4'' is for response ''3'' and ''4'' shown in this Figure, except for the 76 extreme patients, all other patients were covered by these three items at different probabilities for each response category. In summary, the Rasch analysis results suggest these three items met the Rasch measurement model assumption and could be scaled together. Figure 6a shows item information curves for the three pain items. All three information curves peaked toward the middle of the latent trait, but compared to HEP8 (I have discomfort or pain in my stomach area) and GP4 (I have pain), CNS7 (I have pain in my back) was somewhat more informative at more severe levels of pain.
Convergent validity
The pain scores were moderately associated with general health-related quality of life, as measured by the FACT-G (after removing item GP4, which also appears on this scale), with a Pearson's correlation coefficient at baseline of 0.56. For times 2-4, the correlation ranged from 0.69 to 0.74. In the subset of 49 patients who completed the BPI interference scale, the correlation with between the measures was also moderate (r = -0.63 at baseline).
Conclusions
In this secondary data analysis, we evaluated the psychometric properties of a brief, clinically relevant FACT subscale to assess pain in patients with HCC. Results indicated that the three-item pain scale satisfied the assumptions of response monotonicity, adequate unidimensional fit, and local independence, allowing for Rasch analysis. The range of responses on these items sufficiently covered the pain spectrum, and the item-person fit demonstrated adequate coverage for all except the 24 % of patients reporting no pain. Responses on all three items reflected ordered thresholds; however, for the ''pain in the back'' item, the response of ''quite a bit'' was not likely to be endorsed most often at any pain level suggesting little discrimination from the extreme category of ''very much'' pain. There were some subtle differences in the location of peaks for the information curves across the three items. Notwithstanding the inability to distinguish between the two most extreme response levels on the ''pain in the back'' item, its item information curve peaked at slightly lower threshold (more severe) pain levels compared to the ''general pain'' and the ''stomach pain/discomfort'' items. Given that HCC is characterized by underlying liver cirrhosis and accompanying ascites, general pain and stomach pain/discomfort may be more common and less informative at high pain trait levels than back pain.
Based on the scale information curve (Fig. 6b) , the total magnitude of information represented by the scale at its peak was in the 3-4 range, which translates to a reliability coefficient of between 0.66 and 0.75 [23] , similar to that estimated for the baseline assessment using the classical test theory-based internal consistency (Cronbach's alpha) reliability coefficient. Internal consistency of the three-item scale was better at follow-up assessments than at baseline. This might reflect the greater heterogeneity of the baseline sample with regard to the types of pain assessed by the three items, relative to the co-occurrence of back, abdominal, and general pain during follow-up. Nonetheless, for a subscale with only three items, the estimated reliability coefficients and scale information in this study are reasonable. As with any brief scale, end users should be aware that the standard error of measurement will be greater than for longer scales. The addition of items to this HCC-related pain scale might improve its reliability, but at the expense of additional respondent burden. We also found good evidence for convergent validity of the threeitem pain scale with the FACT-G and with the BPI, for the subset of patients with the additional measures.
Treatment strategies for early HCC include surgical resection, liver transplantation, or locoregional therapies, which include radiofrequency-ablation (RFA), cryo-ablation, 90-yttrium, ethanol ablation, or transarterial chemoembolization (TACE) [24, 25] . Following treatment with non-surgical locoregional therapy, sorafenib is the most widely used systemic treatment [26] . Previously used symptom end points in HCC clinical studies, including the pivotal study for sorafenib, have not always been responsive to changes in radiologically measured disease [8] . It is possible that measurement of change in symptom scales that included other symptoms, notably weight loss, jaundice and nausea, along with pain, in HCC clinical studies may have been confounded by side effects of treatment or progression of underlying cirrhosis, which is not responsive to cancer treatment [27] . Non-pain symptoms in HCC may be due to treatment effects and comorbidities unrelated to the cancer and/or may be associated with the location of the lesion not captured in the current analysis.
Pain is an important symptom for some patients with HCC, based on feedback from patients and providers [7, 9] . However, pain data have not been collected routinely as salient end points or intermediary variables in the HCC literature. We believe that this is attributable in part to the challenges inherent in obtaining these data and the lack of perceived value of this type of data. To address these issues, we have developed a brief, clinically relevant scale of pain for patients with HCC. Prior to use as a sole indicator of pain, it would be wise to pair the three-item pain scale with another validated pain measure to support confirmation with external criteria. If future research suggests that the scale is sensitive to change, it may be useful in future clinical trials.
